The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Real-world effectiveness of MSC-FFM in ruxolitinib-refractory aGvHD
⭐GvHD Hub spotlight: Real-world effectiveness of MSC-FFM in RR-aGvHD⭐
Given the poor prognosis of patients with steroid-refractory acute graft-versus-host disease (aGvHD), new treatment options are needed. Bonig et al. from Goethe University, Frankfurt, Germany; Institute Frankfurt, Frankfurt, Germany; University of Washington, Seattle, WA, USA; published an article in the Journal of Translational Medicine discussing the effectiveness and tolerability of salvage treatment with the allogeneic mesenchymal stromal cell-Frankfurt am Main (MSC-FFM) in heavily pre-treated patients with ruxolitinib-refractory aGvHD in real-world clinical settings.
This educational resource is independently supported by Medac. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
